Karen Wagner

Karen Wagner

Board Member

Dr. Karen Wagner is a senior executive and entrepreneur with close to 20 years’ experience in the biopharmaceutical industry. Karen is General Partner at Ysios Capital Partners and her main role at Ysios is to identify and manage therapeutic investments.

Prior to joining Ysios in 2008, Karen was a Global Alliance Director for F. Hoffmann-La Roche in Basel, Switzerland. She joined Roche from GLYCART, a biotech company in the antibody engineering space, which was acquired by Roche in 2005 for 235 million Swiss Francs. Karen has also worked as a consultant.

In addition to Xeltis, Karen serves on the Boards of Aelix Therapeutics and Vivet Therapeutics and is an observer on the Board of Minoryx Therapeutics. She holds a master’s degree in Molecular Biology and a PhD in Cell Biology.